| Virogenomics has obtained rights to technologies in three general disease areas including autoimmune diseases, stroke, and infectious diseases. |
| The autoimmune technology was spun-off in 2004 into a subsidiary named Artielle ImmunoTherapeutics. |
| The stroke technology was recently spun off into its own entity, NeuroProtect, Inc. |
| I D Biopharma, was formed via the consolidation of infectious disease technologies from Virogenomics and additional technologies from Oregon Health & Science University (OHSU). |
| Virogenomics continues to evaluate promising early stage biomedical technology. |
